Cytokine

Galapagos’ R&D Roundtable showcases Toledo program

Tuesday, October 27, 2020 - 3:20pm

Toledo exhibits a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines.

Key Points: 
  • Toledo exhibits a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines.
  • Today, Galapagos also presents new preclinical and healthy volunteer data, and details its broad program to discover and develop multiple series of Toledo compounds with different selectivity profiles, aimed at treating a broad range of autoimmune conditions with important unmet medical need.
  • Galapagos developed innovative chemistry to address a number of selectivity profiles, and we now also show promising preclinical activity in fibrotic models, further broadening the scope of the Toledo program to a second disease paradigm where we built up substantial scientific know-how over the years.
  • Galapagos ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines.

Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile

Tuesday, October 27, 2020 - 1:34pm

In a previous clinical trial, dapansutrile was observed to suppress IL-1 and downstream cytokines and chemokines of the inflammatory cascade in patients with the acute gout flares.

Key Points: 
  • In a previous clinical trial, dapansutrile was observed to suppress IL-1 and downstream cytokines and chemokines of the inflammatory cascade in patients with the acute gout flares.
  • In a second clinical trial in patients with persistent heart failure, the dapansutrile treatment group showed improvement in heart function compared to the placebo group.
  • Activation of NLRP3 initiates Cytokine Release Syndrome (CRS), an intense inflammatory response, that is frequently documented in COVID-19 patients.
  • By downregulating NLRP3 activation, dapansutrile could mitigate against the serious inflammatory effects from the SARS-CoV-2 infection, particularly in high-risk COVID-19 patients.

Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools

Tuesday, October 20, 2020 - 2:00pm

Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.

Key Points: 
  • Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.
  • Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers, said Dr. Marion Jung, CEO of ChromoTek.
  • Dr. Jason Li, CEO of Proteintech said, This new partnership will deliver considerable value to the market.
  • In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade.

Comparative Analysis of COVID-19 Reveals a Cytokine Shower, Not a Storm

Monday, October 19, 2020 - 3:06pm

However, new research from The Feinstein Institutes for Medical Research indicates that COVID-19 does not cause cytokine storms.

Key Points: 
  • However, new research from The Feinstein Institutes for Medical Research indicates that COVID-19 does not cause cytokine storms.
  • The results suggest a potential alternate course of treatments as many clinicians have regularly prescribed anti-cytokine therapies to treat COVID-19.
  • Our understanding of the cytokine responses in COVID-19 continues to evolve, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.
  • Dr. Deutschmans team findings show that a cautious approach is needed to potentially manipulate cytokine levels with drugs.

Viral 'molecular scissor' is next COVID-19 drug target: Coronavirus uses enzymatic cutter for virus production and to disable essential immune proteins

Sunday, October 18, 2020 - 12:10pm

The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.

Key Points: 
  • The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.
  • Information gleaned by the American team helped Polish chemists to develop two molecules that inhibit the cutter, an enzyme called SARS-CoV-2-PLpro.
  • "It stimulates the release of proteins that are essential for the virus to replicate, and it also inhibits molecules called cytokines and chemokines that signal the immune system to attack the infection," Dr. Olsen said.
  • Visit our online Newsroom , and to see how we are battling COVID-19, read inspiring stories on Impact .

Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting

Thursday, October 15, 2020 - 1:00pm

4-1BBL is a costimulatory molecule that can drive T and NK cell proliferation and activation and interferon gamma (IFN) production.

Key Points: 
  • 4-1BBL is a costimulatory molecule that can drive T and NK cell proliferation and activation and interferon gamma (IFN) production.
  • IL-15 is a cytokine that bridges innate and adaptive immunity by promoting NK and T cell proliferation and NK cell cytotoxicity.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • Rubius Therapeutics manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News.

CytoAgents Launches Clinical Trials for GP1681, Treatment of COVID-19 Cytokine Storm

Tuesday, October 13, 2020 - 1:59pm

CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead drug candidate, GP1681, for treatment of COVID-19 cytokine storm, clinically known as hypercytokinemia.

Key Points: 
  • CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead drug candidate, GP1681, for treatment of COVID-19 cytokine storm, clinically known as hypercytokinemia.
  • We are building a powerful treatment platform for respiratory illness that ultimately creates a powerful, lasting solution for cytokine storm and for any respiratory epidemic.
  • GP1681 is a small molecule inhibitor of cytokine release in activated human immune cells that addresses an unmet need for therapeutic treatment.
  • Operating for more than two decades, CMAX conducts successful, world-leading research for local and international clients, specializing in a range of early-phase trials and first-in-human studies.

Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Thursday, October 8, 2020 - 2:15pm

In this report, evidence is provided that Ampion reduces pro-inflammatory cytokine release by activating the immunoregulatory transcription factors PPAR and AhR.

Key Points: 
  • In this report, evidence is provided that Ampion reduces pro-inflammatory cytokine release by activating the immunoregulatory transcription factors PPAR and AhR.
  • In addition, data indicates that Ampion suppresses NF-B and STAT1 pro-inflammatory pathways, suggesting that Ampion acts through these mechanisms to decrease pro-inflammatory transcription factor activity and subsequent inflammatory cytokine production.
  • This publication adds to the growing evidence of the important anti-inflammatory activities of Ampion in various inflammation related conditions, including the dysregulated immune response observed in severe COVID-19 infected patients.
  • Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

TILT Biotherapeutics Announces Two Patients Pass Primary Safety Endpoint in European Cancer Immunotherapy Trial

Monday, September 28, 2020 - 7:00am

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmarks Herlev hospital in Copenhagen.

Key Points: 
  • TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmarks Herlev hospital in Copenhagen.
  • Of the two patients dosed, both have now passed the trials 36-day primary safety endpoint having received three administrations of TILT-123 at the lowest dose.
  • TILT-123s clinical trial (1) is a phase 1, open-label, dose-escalation study of the companys oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2.
  • This should act as a springboard to more European trials, and our first US trials, in other solid tumors.

Study Finds That Children's Immune Response Protects Against COVID-19

Monday, September 21, 2020 - 7:00pm

The patients' blood was tested for the presence of several types of immune cells, antibody responses, and the inflammatory proteins, known as cytokines, that immune cells produce.

Key Points: 
  • The patients' blood was tested for the presence of several types of immune cells, antibody responses, and the inflammatory proteins, known as cytokines, that immune cells produce.
  • Adaptive immunity, the second type of immune response, is more specific and features antibodies and immune cells that target specific viruses or other microbes.
  • Compared with adult patients, pediatric COVID-19 patients in the study possessed significantly higher levels of certain cytokines associated with the innate immune response.
  • "Rather, adult patients respond to coronavirus infection with an over-vigorous adaptive immune response that may promote the inflammation associated with ARDS."